$-2.00 EPS Expected for Arcadia Biosciences, Inc. (RKDA)

March 19, 2018 - By Nellie Frank

 $ 2.00 EPS Expected for Arcadia Biosciences, Inc. (RKDA)

Analysts expect Arcadia Biosciences, Inc. (NASDAQ:RKDA) to report $-2.00 EPS on March, 20 after the close.They anticipate $0.60 EPS change or 23.08 % from last quarter’s $-2.6 EPS. After having $-2.20 EPS previously, Arcadia Biosciences, Inc.’s analysts see -9.09 % EPS growth. The stock decreased 1.37% or $0.58 during the last trading session, reaching $41.91. About 1.23M shares traded or 147.27% up from the average. Arcadia Biosciences, Inc. (NASDAQ:RKDA) has declined 43.32% since March 19, 2017 and is downtrending. It has underperformed by 60.02% the S&P500.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Ratings Coverage

Among 2 analysts covering Arcadia Biosciences (NASDAQ:RKDA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Arcadia Biosciences had 2 analyst reports since May 12, 2017 according to SRatingsIntel. As per Friday, May 12, the company rating was downgraded by PiperJaffray. Piper Jaffray maintained it with “Hold” rating and $100 target in Friday, July 21 report.

Arcadia Biosciences, Inc., an agricultural biotechnology trait company, develops traits that enhance food, feed, and fiber crops worldwide. The company has market cap of $89.44 million. The firm offers a suite of agricultural yield traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, herbicide tolerance, and heat tolerance traits, as well as yield and agronomic trait stacks primarily for food crops, such as corn, rice, wheat, and soybean. It currently has negative earnings. It also provides agricultural product quality traits comprising gamma linolenic acid safflower oil to manufacturers of nutritional supplements, medical foods, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.